Cinnamomum burmannii improves insulin serum level in the normal obese subjects: preliminary study

Hari Hendarto1, Flori R Sari2*, Chris Adhyanto3
1Department of Internal Medicine, 2Department of Pharmacology, 3Department of Biochemistry, Faculty of Medicine and Health Sciences, Syarif Hidayatullah Islamic State University, Ciputat, Indonesia

DOI: http://dx.doi.org/10.19108/JMedSci005001201808

ABSTRACT

Obesity is characterized with excessive accumulation of the body fat which occurs when the energy intake exceeds the expenditure. It is routinely associated with insulin resistance and hyperinsulinemia. Additionally, suppressing insulin level protects female mice from weight gaining. Cinnamon (Cinnamomum burmannii (Ness) Bl. Cortex) suppresses hyperinsulinemia condition in the type 2 diabetic rat suggesting the possible beneficial its role in the obesity. We aimed to investigate the effect of Cinnamon extract in the normal obese subjects. In this preliminary cross-over clinical trial, 24 normal obese subjects were recruited and divided randomly into two groups i.e. treatment and placebo. Two grams of the cinnamon extract were given twice daily for 56 days in the treatment group. Normal obese subjects given placebo were allocated as the placebo group. After the treatment, each of the group ran a one month run-in period, then the groups were cross-overed for the next 56 days. Body mass index (BMI), insulin serum level, cholesterol and triglyceride plasma levels were measured at the beginning and at the end of the study.

No diet restriction nor exercise intervention was given during the study. At the end of the study, BMI in the treatment group (58%) were slightly reduced when compared to the placebo group (33%), however, it was not significantly different (p>0.05). Moreover, significantly reduction in the insulin serum level was observed in 63% subject in the treatment group compared to 33% subject in the placebo group (p < 0.05). Additionally, there were no significant differences of cholesterol and triglyceride plasma level observed in the both group. In conclusion, cinnamon extract may give beneficial role in the normal obese subjects by suppressing the serum insulin level. Further studies are required to elucidate the specific role of cinnamon in preventing weight gain.

ABSTRAK


* corresponding author: florisari@unjkt.ac.id
INTRODUCTION

Obesity is a metabolic disorder characterized with excessive expansion of adipose tissue due to imbalances between nutrient intake and energetic activity. Obesity has remarkably increased worldwide and leads to significant morbidity and mortality related to cardiovascular disease, metabolic syndrome, type 2 diabetes, hypertension, degenerative joint disease and some kinds of cancer. It is affecting 33% of adults in the United States and becomes the most common public health problems. Some strategies have been proposed to reduce enormous body weight in the obese state by inhibiting fat absorption in the gut or suppressing appetite in the brain. Recently, it is found that insulin resistance and hyperinsulinemia are the key characteristics of obesity which contributes to its further complication on health. In the obese state, compensatory rise of insulin due to hyperglycemia, may lead to insulin resistance. Furthermore, hyperinsulinemia may promote obesity, resulting in a vicious cycle between obesity, insulin resistance and hyperinsulinemia. It has been reported that attenuating hyperinsulinemia in the experimental young female mice provides protection against obesity reducing insulin secretion may promote weight loss in obese adults with insulin hypersecretion.

Conclusively, reducing insulin secretion may have beneficial role in the strategy of obesity treatment. Cinnamomum burmannii (Ness) BI. Cortex, widely known in Indonesia as cinnamon or kayu manis, cassia in Padang and Batavia, is an endogenous plant that has been traditionally used as spices, herb and medicine. It is currently marketed as a supplemental herbal for diabetes mellitus, dyslipidemia and glucose intolerance since experimental. Clinical evidence showed that cinnamon has a role as insulin sensitizing agent. In 3T3L1 adipocyte tissue, cinnamon extract stimulates glucose uptake and glycogen synthesis and further activates glycogen synthase. Additionally, cinnamon bioactive component stimulates enzymatic reaction of phosphorylation and dephosphorylation, confirming its role as an insulin mimetic.

Furthermore, cinnamon extract may decrease the blood glucose level and stimulate glucose uptake in the experimental type 1 diabetic
rat or type 2 diabetic mice.\textsuperscript{17-20} Recently, evidences have been reported that cinnamon bioactive components, proanthocyanidin and cinnamaldehyde, could improve the formation of pancreatic islet polypeptide and suppress hyperinsulinemia condition in the type 2 diabetic rat.\textsuperscript{21-25}

In the clinical setting, daily consumption of 1.3 or 6 g cinnamon supplement reduced the blood glucose level up to 29\% in the type 2 diabetic patients\textsuperscript{21} and routine consumption of 3 g cinnamon supplement in eight weeks reduced body weight and body mass index (BMI) in type 2 diabetic patients.\textsuperscript{25} These mechanisms may be mediated through the role of cinnamon in improving the body composition and attenuating lipogenic processes in the liver and adipose tissue.\textsuperscript{26-28} Conversely, another study reported that 4 month treatment with a dietary supplement containing cinnamon, chromium and carnosine decreased fasting plasma glucose (FPG) and increased fat-free mass. However, there was no difference with placebo with respect to body weight and BMI in overweight or obese prediabetic subjects.\textsuperscript{29} Despite our significant understanding of the role of cinnamon in the improvement of diabetes, the roles of cinnamon in obesity and its insulin regulation are largely unknown. In the present study, we investigated the effect of cinnamon extract in the normal obese subjects.

MATERIALS AND METHODS

Cinnamon burmannii extract

Cinnamon extract was prepared in a capsules preparation by UD Rachma Sari and certified by the National Agency of Drug and Food Control, Republic of Indonesia (TR 123365801). Each cinnamon capsules contained two g of cinnamon extract. Placebo capsules were packaged as the same as the cinnamon capsule. Both the cinnamon and placebo capsules were packaged in plastic bag containing 14 capsules (two capsules of two g for 7 days) and prepared for distribution of the subjects. Subjects received one capsule twice daily (with the total dose of 4 g/day) for 56 days. The dose were decided based on two previous studies using dose range from 1 - 6 g/day.\textsuperscript{24-25} Subjects were evaluated every 7 days for supplement compliance until the end of the study. Compliance was monitored by capsule count, subjects interview and daily diary analysis.

Design

The design of this preliminary study was randomized cross-over clinical trial study. The study was divided in two phase, in each of the phase every subject received 56 days of capsules (treatment or placebo). Subjects were recruited and allocated randomly into two groups i.e. treatment and placebo. Cinnamon capsules were given for 56 days in normal obese subjects in the treatment group. Another group of normal obese subjects were given placebo as the placebo group. After finishing 56 days treatment, each of the group ran a one month run-in period, and then the groups were cross-overs for the next 56 days. Subjects were not informed which treatment they have received until the end of the study.

Study population

This study was conducted in the Faculty of Medicine and Health Science, Islamic State University and was approved by the Ethics Committee and Human Studies Review Board of Faculty of Medicine and Health Science, Islamic State University. Selection criteria for the study were adult normal obese subjects with BMI $\geq$ 23 kg/m$^2$ and age ranged from 18 to 70 year old. Subjects were excluded from the study if they have: degenerative
disease (hypertension, diabetes mellitus, coronary artery disease, atherosclerosis), cancer, scheduled diet process, pregnancy, breastfeeding, long term pharmacotherapy (chemotherapy, corticosteroid, insulin sensitizing agent, anti-hypertension and anti-cholesterol).

Follow up and outcome measures

Body mass index were measured by dividing body weight (kg) with squared of body height (m). The serum insulin level was measured by ELISA technique using ELISA insulin kit (Calbiotech, Spring Valley, CA, USA). In brief, subjects sera were incubated for 60 minutes with insulin enzyme conjugate, washed, added with TMB substrat for 15 min. After the addition of stop solution, sera were analyzed by ELISA reader. The plasma cholesterol level was measured by cholesterol esterase/cholesterol oxidase technique using cholesterol kit (Sclavo Diagnostics, Siena, Italy). The plasma triglyceride level was measured by triglyceride kit (Diasys Diagnostic System, Holzheim, Germany). Subjects were followed up every 7 days, however, outcome measures were conducted only on day 1 and day 56. At each visits, the occurrence of study outcomes was ascertained according to the intention-to-treat principle.

Data analysis

The variable of this study were the BMI, the serum insulin level, the plasma cholesterol and triglyceride levels. All variable data from the recruited patients were included in the analysis. Comparison among groups was performed using one-way analysis of variance (ANOVA) or student's t-test, wherever applicable. A p < 0.05 was considered as statistically significant.

RESULTS

Baseline characteristics

The characteristics of subjects were summarized in table 1. Twenty four normal obese subjects were recruited and followed up every 7 days until the end of the study. None of them were dropped out during the study. No significant differences of BMI, insulin serum level, cholesterol plasma level and triglyceride plasma level were observed among the groups (p > 0.05).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo group</th>
<th>Treatment group</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n=24</td>
<td>n=24</td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>12</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Female</td>
<td>12</td>
<td>12</td>
<td></td>
</tr>
<tr>
<td>Body Mass Index (kg m²)</td>
<td>28.9 ± 4.8</td>
<td>28.9 ± 5.0</td>
<td>0.9</td>
</tr>
<tr>
<td>Insulin (mg dl.)</td>
<td>23.6 ± 22.2</td>
<td>19.4 ± 14.3</td>
<td>0.4</td>
</tr>
<tr>
<td>Cholesterol (mg dl.)</td>
<td>164 ± 41</td>
<td>171 ± 27</td>
<td>0.5</td>
</tr>
<tr>
<td>Triglyceride (mg dl.)</td>
<td>121 ± 70</td>
<td>111 ± 66</td>
<td>0.6</td>
</tr>
</tbody>
</table>

Effect of cinnamon on BMI and insulin serum level

The effect of cinnamon extract on the BMI and the serum insulin level were summarized in table 2. There was no significantly different on the BMI observed between the placebo and the treatment group, however, slight decrease of 0.1 point was observed.
The serum insulin level increased 8.2 point, however, it was not significantly different. The serum insulin was decreased in 8 subjects received placebo (33%) and increased in the rest of the subjects. Conversely, cinnamon extract decreased the serum insulin level in 15 subjects (63%). Briefly, the serum insulin level was significantly higher on day 1 (19.4 ± 14.3 mg/dL) than on day 56 (16.6 ± 16.4 mg/dL) in the treatment group (p<0.05). No significantly different in plasma cholesterol and triglyceride levels of the both group on day 1 and on day 56 were observed (p > 0.05).

<table>
<thead>
<tr>
<th>Variable</th>
<th>Placebo</th>
<th>Treatment</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Day 1</td>
<td>Day 56</td>
<td>Day 1</td>
</tr>
<tr>
<td>Body Mass Index (kg m²)</td>
<td>28.9 ± 4.8</td>
<td>28.9 ± 4.9</td>
<td>28.9 ± 5.0</td>
</tr>
<tr>
<td>Insulin (mg dl.)</td>
<td>23.6 ± 22.2</td>
<td>31.8 ± 27.3</td>
<td>19.4 ± 14.3</td>
</tr>
<tr>
<td>Cholesterol (mg dl.)</td>
<td>164 ± 41</td>
<td>169 ± 18</td>
<td>171 ± 27</td>
</tr>
<tr>
<td>Triglyceride (mg dl.)</td>
<td>121 ± 70</td>
<td>135 ± 84</td>
<td>111 ± 66</td>
</tr>
</tbody>
</table>

**DISCUSSION**

The salient finding of our research are: (1) cinnamon extract decreased the level of insulin serum in 63% subjects and (2) cinnamon extract decreased significantly the level of insulin serum in 56 days compared to the placebo. In the obese state, insulin may elevate as a compensatory mechanism due to chronic hyperglycemia. Additionally, the chronic elevation of insulin serum level may decrease the insulin responsiveness in the tissues and lead to insulin resistance. Chronic hyperglycemia and hyperinsulinemia work reciprocally and worsen the obese state, resulting in a vicious cycle between obesity, insulin resistance and hyperinsulinemia.

Clinical and experimental evidence have shown that attenuating hyperinsulinemia not only promote weight loss but also provide protection against obesity. Cinnamon has been widely used as spices, herb and traditional medicine. It has been reported that cinnamon exerts potent anti-diabetic effects through its role as insulin mimetic and insulin sensitizing agent. Moreover, cinnamon gives beneficial role in the type 2 diabetic patient by reducing significantly plasma blood glucose level. We have shown in this study that cinnamon extract decreased the level of insulin serum in 63% normal obese subjects and it decreased significantly the level of insulin serum in 56 days of study. Our results were consistent with the previous finding that cinnamon component of proanthocyanidin improves the formation of pancreatic islet polypeptide and its cinnamonaldehyde suppresses hyperinsulinemia condition.

Additionally, cinnamon extract decreased the BMI of the subjects. However, it was not significantly different. Previous study has shown that routine consumption of 3 g cinnamon supplement in eight weeks reduced body weight and BMI in type 2 diabetic patient. These mechanisms may be mediated through the role of cinnamon in improving the body composition and attenuating lipogenic processes in the liver and adipose tissue.
Another study reported that 4 month treatment with a dietary supplement containing cinnamon, chromium and carnosine decreased fasting plasma glucose (FPG) and increased fat-free mass, however, there was no difference versus placebo with respect to body weight and BMI in overweight or obese pre-diabetic subjects. We have concluded that negative result of cinnamon on the BMI in our study may be due to differences in the dose regimen and duration. We should give the proper regimen with longer treatment to evaluate the long-term effect of cinnamon in preventing the weight gain.

Some strategies have been proposed to reduce excessive body weight in the obese state by inhibiting fat absorption in the gut or suppressing appetite in the brain. Recently, it is found that insulin resistance and hyperinsulinemia are the key characteristics of obesity which contributes to its further complication on health. Consistent with the previous finding, we have shown that cinnamon may give beneficial role in obesity not only by increasing insulin sensitivity but also by attenuating hyperinsulinemia condition.

CONCLUSIONS

Cinnamon extract may give beneficial role in the normal obese subjects by suppressing the serum insulin level. Further studies are required to elucidate the specific role of cinnamon in preventing weight gain.

ACKNOWLEDGEMENTS

Authors would like to thank subjects who participated in this study.

REFERENCES


